Partnering with global sponsors including Novartis, AstraZeneca, Roche, GSK, Sandoz, and Janssen across rheumatology, infectious disease, and osteoporosis.
Phase III · Novartis
Ianalumab
Diffuse Cutaneous Systemic Sclerosis
Principal InvestigatorPhase III · AstraZeneca
Anifrolumab (DAISY)
Systemic Sclerosis
Principal InvestigatorPhase III · AstraZeneca
Anifrolumab
Active Proliferative Lupus Nephritis
Principal InvestigatorPhase IV · Janssen
Guselkumab
Psoriatic Arthritis
Principal InvestigatorPhase IV · GSK
Denosumab (DenOsteoRel™)
Post-menopausal Osteoporosis
Principal InvestigatorPhase III · Novartis
Secukinumab
Rheumatoid Arthritis (anti-TNF inadequate response)
Principal InvestigatorPhase II · Sandoz
Rituximab Biosimilar (GP2013)
RA refractory to DMARDs & anti-TNF
Principal InvestigatorPhase IV · Roche
Tocilizumab
Active Rheumatoid Arthritis
Principal InvestigatorPhase IV · Novartis
Zolendronic Acid (Aclasta)
Glucocorticoid-induced Osteoporosis
Principal InvestigatorPhase III · Enzene Biosciences
Teriparatide (Enzene Biosciences)
Postmenopausal Osteoporosis
Principal InvestigatorPhase III · GSK
Denosumab
Indian postmenopausal women with osteoporosis
Principal InvestigatorPhase III · Janssen
Pimodivir
Influenza A (hospitalised and non-hospitalised)
Principal InvestigatorPhase II · Hemispherx
Interferon Alpha-N3
Severe Influenza
Principal InvestigatorPhase III · Biocryst
Peramivir IV
Adults hospitalised with serious influenza
Co-InvestigatorPhase III · Independent
Rabies Vaccine (SURE RAB)
Immunogenicity and safety
Principal InvestigatorInvestigator-initiated · IRA / DRA Grant
suPAR Biomarker
Rheumatoid Arthritis disease activity
Principal InvestigatorPhase III · Celtic Therapeutics
KIACTA (Eprodisate)
AA Amyloidosis (renal function decline)
Principal InvestigatorObservational · Novartis
AZURE (Zolendronic Acid)
Osteoporotic patients in real-world setting
Principal InvestigatorPhase IV · AstraZeneca
SOLID Study (Lipid Abnormality)
Diabetics
Principal InvestigatorInvestigator-initiated · SGRH
Lung Cancer & CAD Screening
Low-dose CT thorax in asymptomatic high-risk individuals
Principal Investigator